95 related articles for article (PubMed ID: 31288376)
1. β-Catenin/TCF4 Complex-Mediated Induction of the
Aono S; Hatanaka A; Hatanaka A; Gao Y; Hippo Y; Taketo MM; Waku T; Kobayashi A
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31288376
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of the Wnt/β-catenin signaling pathway by Cacnb4.
Rima M; Daghsni M; Lopez A; Fajloun Z; Lefrancois L; Dunach M; Mori Y; Merle P; Brusés JL; De Waard M; Ronjat M
Mol Biol Cell; 2017 Dec; 28(25):3699-3708. PubMed ID: 29021340
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of ASIC1a promotes proliferation via activation of the β-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer.
Jin C; Yuan FL; Gu YL; Li X; Liu MF; Shen XM; Liu B; Zhu MQ
Oncotarget; 2017 Apr; 8(16):25977-25988. PubMed ID: 27462920
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide ChIP-seq analysis of TCF4 binding regions in colorectal cancer cells.
Chen C; Lu Y; Liu J; Li L; Zhao N; Lin B
Int J Clin Exp Med; 2014; 7(11):4253-9. PubMed ID: 25550940
[TBL] [Abstract][Full Text] [Related]
5. Identification roles of NFE2L3 in digestive system cancers.
Li F; Wen Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):150. PubMed ID: 38514488
[TBL] [Abstract][Full Text] [Related]
6. New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome.
Kobayashi A; Waku T
Cancer Sci; 2020 Jan; 111(1):6-14. PubMed ID: 31742837
[TBL] [Abstract][Full Text] [Related]
7. Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors.
Kobayashi A
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962187
[TBL] [Abstract][Full Text] [Related]
8. NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression.
Waku T; Katayama H; Hiraoka M; Hatanaka A; Nakamura N; Tanaka Y; Tamura N; Watanabe A; Kobayashi A
Mol Cell Biol; 2020 Jun; 40(14):. PubMed ID: 32366381
[TBL] [Abstract][Full Text] [Related]
9. Differential and overlapping targets of the transcriptional regulators NRF1, NRF2, and NRF3 in human cells.
Liu P; Kerins MJ; Tian W; Neupane D; Zhang DD; Ooi A
J Biol Chem; 2019 Nov; 294(48):18131-18149. PubMed ID: 31628195
[TBL] [Abstract][Full Text] [Related]
10. NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor.
Bury M; Le Calvé B; Lessard F; Dal Maso T; Saliba J; Michiels C; Ferbeyre G; Blank V
Cell Rep; 2019 Nov; 29(6):1469-1481.e9. PubMed ID: 31693889
[TBL] [Abstract][Full Text] [Related]
11. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein.
Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A
Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008
[TBL] [Abstract][Full Text] [Related]
12. Defining the Functional Targets of Cap'n'collar Transcription Factors NRF1, NRF2, and NRF3.
Ibrahim L; Mesgarzadeh J; Xu I; Powers ET; Wiseman RL; Bollong MJ
Antioxidants (Basel); 2020 Oct; 9(10):. PubMed ID: 33096892
[TBL] [Abstract][Full Text] [Related]
13. NFE2L3 promotes malignant behavior and EMT of human hepatocellular carcinoma (HepG2) cells via Wnt/β‑catenin pathway.
Ren Y; Wang Y; Hao S; Yang Y; Xiong W; Qiu L; Tao J; Tang A
J Cancer; 2020; 11(23):6939-6949. PubMed ID: 33123284
[No Abstract] [Full Text] [Related]
14.
Li Y; Sun J; Granados-López AJ; Chu Z; Zhang H
J Gastrointest Oncol; 2023 Oct; 14(5):2124-2133. PubMed ID: 37969834
[TBL] [Abstract][Full Text] [Related]
15. NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5.
Gurri S; Siegenthaler B; Cangkrama M; Restivo G; Huber M; Saliba J; Dummer R; Blank V; Hohl D; Werner S
EMBO Mol Med; 2023 Nov; 15(11):e17761. PubMed ID: 37807968
[TBL] [Abstract][Full Text] [Related]
16. NFE2L3 drives hepatocellular carcinoma cell proliferation by regulating the proteasome-dependent degradation of ISGylated p53.
Ren Y; Yang J; Ding Z; Zheng M; Qiu L; Tang A; Huang D
Cancer Sci; 2023 Sep; 114(9):3523-3536. PubMed ID: 37350063
[TBL] [Abstract][Full Text] [Related]
17. NRF3 activates mTORC1 arginine-dependently for cancer cell viability.
Hirose S; Waku T; Tani M; Masuda H; Endo K; Ashitani S; Aketa I; Kitano H; Nakada S; Wada A; Hatanaka A; Osawa T; Soga T; Kobayashi A
iScience; 2023 Feb; 26(2):106045. PubMed ID: 36818298
[TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer.
Liu M; Wei H; Yang J; Chen X; Wang H; Zheng Y; Wang Y; Zhou Y
Front Genet; 2022; 13():916973. PubMed ID: 35846126
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
